Review findings

Related Reading # AOD-9604 research studies and evidence AOD-9604 dosing protocols AOD-9604 side effects profile Adipotide research guide CJC-1295 DAC research guide Stay current on AOD-9604 research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

AOD-9604: HGH Fragment for Fat Loss Research | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?

Restore access No thanks, continue reading Related Reading Peptide HGH Fragment 176-191 lipolytic growth hormone fragment Peptide HGH 191AA full-length recombinant growth hormone Article AOD-9604, Tesamorelin & MOTS-C Stack Guide How AOD-9604 works at the cellular level Overview of AOD-9604 benefits and applications Scientific Details Molecular Formula C78H123N23O23S2 Molecular Weight 1815.12 Da CAS Number 221231-10-3 Sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe What is AOD-9604? # AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide corresponding to residues 176-191 of the C-terminal region of human growth

Growth Hormone Anti-Aging & Longevity CJC-1295 DAC CJC-1295 DAC: Long-acting GHRH analog with extended half-life.

following potential benefits of AOD-9604: Stimulates fat metabolism (lipolysis) without the growth-promoting effects of full-length hGH.

Why: Confirm AOD-9604 does not affect GH/IGF-1 axis (it should not) Thyroid panel (TSH, Free T4) When: Baseline Why: Rule out thyroid-related metabolic issues CMP When: Baseline Why: Liver and kidney function baseline Fasting insulin When: Baseline Why: Baseline insulin sensitivity 💡 Key Considerations → Administer on empty stomach in morning for best results → No fasting insulin or glucose changes expected → Contraindication: Avoid in pregnancy or active cancer; failed Phase IIb clinical trial and was abandoned by the pharmaceutical developer Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — free.

Restore access No thanks, continue reading Related Reading Peptide HGH Fragment 176-191 lipolytic growth hormone fragment Peptide HGH 191AA full-length recombinant growth hormone Article AOD-9604, Tesamorelin & MOTS-C Stack Guide How AOD-9604 works at the cellular level Overview of AOD-9604 benefits and applications Scientific Details Molecular Formula C78H123N23O23S2 Molecular Weight 1815.12 Da CAS Number 221231-10-3 Sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe What is AOD-9604? # AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide corresponding to residues 176-191 of the C-terminal region of human growth

146367): The study demonstrated demonstrated that oral AOD-9604 at 500 mcg/kg/day reduced body weight gain by over of 50% in obese Zucker rats over 19 days, with increased lipolytic activity and no adverse effect on insulin sensitivity.

Peptide Protocol Wiki June 4, 2026 Retatrutide BPC-157 Tesamorelin + 6 more Guide 5 min read FDA Peptide Categories Explained: Category 1 vs Category 2 (2026) Understand the FDA peptide classification system.

Peptide Protocol Wiki March 7, 2026 BPC-157 TB-500 AOD-9604 + 11 more You Might Also Like Related content you may find interesting Peptide Metabolic Cagrilintide Peptide Metabolic Mazdutide Peptide Metabolic Retatrutide Peptide Metabolic Semaglutide Table of Contents What is AOD-9604?

Covers pulsatile GH release, Ipamorelin stack synergy, dosing, and side eff

Where to Find AOD-9604 Compare all vendor prices → Research-grade suppliers verified by our scoring methodology.

Peptide Protocol Wiki March 7, 2026 BPC-157 TB-500 AOD-9604 + 11 more You Might Also Like Related content you may find interesting Peptide Metabolic Cagrilintide Peptide Metabolic Mazdutide Peptide Metabolic Retatrutide Peptide Metabolic Semaglutide Table of Contents What is AOD-9604?

Peptide Protocol Wiki June 4, 2026 Retatrutide BPC-157 Tesamorelin + 6 more Guide 5 min read FDA Peptide Categories Explained: Category 1 vs Category 2 (2026) Understand the FDA peptide classification system.

AOD-9604 was developed by Metabolic Pharmaceuticals Ltd.

The proposed mechanism involves: Beta-3 adrenergic receptor upregulation : Chronic treatment with AOD-9604 increases the expression of beta-3 adrenergic receptors (beta-3 AR) on adipocytes.

Cartilage Repair Potential # More recently, AOD-9604 has been investigated for cartilage and joint repair.

s of full-length hGH • Does not affect serum IGF-1 levels or carbohydrate metabolism at studied doses • Extensive human safety database from over 900 participants across six clinical trials • Investigated for cartilage repair and osteoarthritis applications • Does not compete for the hGH receptor or induce cell proliferation Community-Reported Side Effects Anecdotal ? 📋 Protocol Quick-Reference Fat metabolism research and body composition improvement 💉 Dosing Amount 250-300 mcg Frequency Once daily Duration 8-12 weeks 💊 Administration Route SC Schedule Once daily Timing Morning on empty stomach, 30 minutes before first meal ✓ Rotate injection sites 📅 Cycle Duration 8-12 weeks Repeatable Yes Preparation & Storage Diluent: Bacteriostatic water Storage: Store lyophilized AOD-9604 at -20 degrees Celsius in a sealed, desiccated container.

ts receiving oral AOD-9604 (1 mg/day) lost an average of 2.6 kg compared to 0.8 kg in the placebo group.

Peptide Protocol Wiki March 30, 2026 BPC-157 Thymosin Alpha-1 AOD-9604 + 16 more Guide 8 min read Weight Loss Peptides: Mechanisms, Evidence, and How They Compare A mechanism-focused guide to weight loss peptides — how GLP-1, GIP, and glucagon pathways drive fat loss, how single, dual, and triple agonists compare, and what the clinical evidence actually shows.

e in metabolic syndrome management Safety profile supporting metabolic applications Novel mechanism distinct from other anti-obesity approaches Safety Profile # The most notable aspect of AOD-9604's clinical history is its extensive safety database.

s of full-length hGH • Does not affect serum IGF-1 levels or carbohydrate metabolism at studied doses • Extensive human safety database from over 900 participants across six clinical trials • Investigated for cartilage repair and osteoarthritis applications • Does not compete for the hGH receptor or induce cell proliferation Community-Reported Side Effects Anecdotal ? 📋 Protocol Quick-Reference Fat metabolism research and body composition improvement 💉 Dosing Amount 250-300 mcg Frequency Once daily Duration 8-12 weeks 💊 Administration Route SC Schedule Once daily Timing Morning on empty stomach, 30 minutes before first meal ✓ Rotate injection sites 📅 Cycle Duration 8-12 weeks Repeatable Yes Preparation & Storage Diluent: Bacteriostatic water Storage: Store lyophilized AOD-9604 at -20 degrees Celsius in a sealed, desiccated container.

dose: 300 mcg · cycle: Cycle · timing: Morning · frequency: Once daily · reconstitution: Bacteriostatic

ts receiving oral AOD-9604 (1 mg/day) lost an average of 2.6 kg compared to 0.8 kg in the placebo group.

dose: 1 mg · route: oral

146367): The study demonstrated demonstrated that oral AOD-9604 at 500 mcg/kg/day reduced body weight gain by over of 50% in obese Zucker rats over 19 days, with increased lipolytic activity and no adverse effect on insulin sensitivity.

dose: 500 mcg · route: oral

s of full-length hGH • Does not affect serum IGF-1 levels or carbohydrate metabolism at studied doses • Extensive human safety database from over 900 participants across six clinical trials • Investigated for cartilage repair and osteoarthritis applications • Does not compete for the hGH receptor or induce cell proliferation Community-Reported Side Effects Anecdotal ? 📋 Protocol Quick-Reference Fat metabolism research and body composition improvement 💉 Dosing Amount 250-300 mcg Frequency Once daily Duration 8-12 weeks 💊 Administration Route SC Schedule Once daily Timing Morning on empty stomach, 30 minutes before first meal ✓ Rotate injection sites 📅 Cycle Duration 8-12 weeks Repeatable Yes Preparation & Storage Diluent: Bacteriostatic water Storage: Store lyophilized AOD-9604 at -20 degrees Celsius in a sealed, desiccated container.

AOD-9604: HGH Fragment for Fat Loss Research | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?

Start the 7-step beginner guide Peptides Side Effects New Directory Learn Tools Blog News About AOD-9604 📋 Overview 🧬 Molecule 🔄 Similar ⚠️ Side Effects 💉 Dosing 🔬 Research 🚨 Risks 👥 Community 📊 Community Data Home Peptides AOD-9604 Weight Loss & Metabolism Healing & Tissue Repair discontinued AOD-9604 Also known as: Anti-Obesity Drug 9604, hGH Fragment 176-191, AOD9604, Tyr-hGH(177-191) Research compiled by Peptide Protocol Wiki 📅 Updated February 8, 2026 Citations Verified TL;DR AOD-9604 is a synthetic 16-amino acid peptide derived from the C-terminal region of human growth hormone (residues 176-191) with an N-terminal tyrosine substitution.

AOD-9604 was administered orally and demonstrated no significant adverse effects.

Key safety findings from clinical trials include: No effect on IGF-1 : Serum IGF-1 levels unchanged during treatment No hyperglycemia : Unlike hGH, AOD-9604 does not impair glucose metabolism No growth effects : No cell proliferation or growth-promoting activity detected Well tolerated : Adverse event rates similar to placebo across clinical trials No hormonal disruption : No significant effects on thyroid, adrenal, or gonadal function Evidence Gaps and Limitations # AOD-9604 failed its primary weight loss endpoint in the largest clinical trial Cartilage repair evidence is primarily preclinical The mechanism of action for cartilage effects is not well characterized Long-term safety data beyond 24 weeks is limited Optimal dosing for cartilage applications has not been established Products available from research chemical suppliers lack pharmaceutical standardization Whether oral bioavailability is sufficient for systemic effects remains debated The relationship between AOD-9604 and full-length hGH in cartilage repair is unclear Key Research Findings # Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone , published in Hormone Research (Ng FM et al., 2000;

146367): The study demonstrated demonstrated that oral AOD-9604 at 500 mcg/kg/day reduced body weight gain by over of 50% in obese Zucker rats over 19 days, with increased lipolytic activity and no adverse effect on insulin sensitivity.

Related Reading # AOD-9604 research studies and evidence AOD-9604 dosing protocols AOD-9604 side effects profile Adipotide research guide CJC-1295 DAC research guide Stay current on AOD-9604 research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

What are the side effects of AOD-9604?

Reported side effects of AOD-9604 include injection site reactions.

Most reported side effects are mild and transient.

Consult the detailed side effects profile for full information.

Covers Drug Affinity Complex mechanism, GH/IGF-1 elevation, dosing, and side effects.

Report an Error Related Articles Guide 9 min read Best Peptides to Stack with Retatrutide (2026 Research Guide) A 2026 research-focused review of the peptides most often discussed alongside retatrutide for GI side effects, lean-mass preservation, hair and skin changes, sleep, and adjunct fat loss — what the literature does and does not support.

Peptide Directory All Peptides Metabolic Anti-Obesity Anti-Aging Immune Hormonal View All Categories Directory Peptide Vendors Analytics Labs Side Effects Database Report a Side Effect Learn Start Here What Are Peptides?

Why: Confirm AOD-9604 does not affect GH/IGF-1 axis (it should not) Thyroid panel (TSH, Free T4) When: Baseline Why: Rule out thyroid-related metabolic issues CMP When: Baseline Why: Liver and kidney function baseline Fasting insulin When: Baseline Why: Baseline insulin sensitivity 💡 Key Considerations → Administer on empty stomach in morning for best results → No fasting insulin or glucose changes expected → Contraindication: Avoid in pregnancy or active cancer; failed Phase IIb clinical trial and was abandoned by the pharmaceutical developer Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — free.

Peptide Protocol Wiki March 7, 2026 BPC-157 TB-500 AOD-9604 + 11 more You Might Also Like Related content you may find interesting Peptide Metabolic Cagrilintide Peptide Metabolic Mazdutide Peptide Metabolic Retatrutide Peptide Metabolic Semaglutide Table of Contents What is AOD-9604?

Peptide Protocol Wiki June 4, 2026 Retatrutide BPC-157 Tesamorelin + 6 more Guide 5 min read FDA Peptide Categories Explained: Category 1 vs Category 2 (2026) Understand the FDA peptide classification system.

Peptide Protocol Wiki March 30, 2026 BPC-157 Thymosin Alpha-1 AOD-9604 + 16 more Guide 8 min read Weight Loss Peptides: Mechanisms, Evidence, and How They Compare A mechanism-focused guide to weight loss peptides — how GLP-1, GIP, and glucagon pathways drive fat loss, how single, dual, and triple agonists compare, and what the clinical evidence actually shows.

Restore access No thanks, continue reading Related Reading Peptide HGH Fragment 176-191 lipolytic growth hormone fragment Peptide HGH 191AA full-length recombinant growth hormone Article AOD-9604, Tesamorelin & MOTS-C Stack Guide How AOD-9604 works at the cellular level Overview of AOD-9604 benefits and applications Scientific Details Molecular Formula C78H123N23O23S2 Molecular Weight 1815.12 Da CAS Number 221231-10-3 Sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe What is AOD-9604? # AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide corresponding to residues 176-191 of the C-terminal region of human growth

Related Reading # AOD-9604 research studies and evidence AOD-9604 dosing protocols AOD-9604 side effects profile Adipotide research guide CJC-1295 DAC research guide Stay current on AOD-9604 research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

Restore access No thanks, continue reading Related Reading Peptide HGH Fragment 176-191 lipolytic growth hormone fragment Peptide HGH 191AA full-length recombinant growth hormone Article AOD-9604, Tesamorelin & MOTS-C Stack Guide How AOD-9604 works at the cellular level Overview of AOD-9604 benefits and applications Scientific Details Molecular Formula C78H123N23O23S2 Molecular Weight 1815.12 Da CAS Number 221231-10-3 Sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe What is AOD-9604? # AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide corresponding to residues 176-191 of the C-terminal region of human growth

Restore access No thanks, continue reading Related Reading Peptide HGH Fragment 176-191 lipolytic growth hormone fragment Peptide HGH 191AA full-length recombinant growth hormone Article AOD-9604, Tesamorelin & MOTS-C Stack Guide How AOD-9604 works at the cellular level Overview of AOD-9604 benefits and applications Scientific Details Molecular Formula C78H123N23O23S2 Molecular Weight 1815.12 Da CAS Number 221231-10-3 Sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe What is AOD-9604? # AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide corresponding to residues 176-191 of the C-terminal region of human growth